Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Hyper-CVAD plus ofatumumab vs hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis. Have a read: https://www.m3india.in/contents/journal/hyper-cvad-plus-ofatumumab-vs-hyper-cvad-plus?utm_campaign=unset&utm_medium=share&utm_source=ref_wa